• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    MARPAI REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS

    3/26/25 4:15:00 PM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care
    Get the next $MRAI alert in real time by email

    MARPAI EXHIBITS STRONG, ONGOING FINANCIAL IMPROVEMENT

    TAMPA, Fla., March 26, 2025 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (OTCQX:MRAI), a technology platform company, which operates as a national Third-Party Administrator (TPA) through its subsidiaries and is transforming the $22 billion TPA market by offering affordable, intelligent, healthcare solutions to self-funded employer health plans, today announced the financial results for the fourth quarter and fiscal year 2024. The Company expects to hold a webcast to discuss the results on March 27, 2025.

    Q4 2024 Financial Highlights:

    • Net revenues were $6.6 million in Q4 2024, a decrease of $0.4 million, or 6.0% lower than Q3 2024.
    • Operating expenses were $5.3 million in Q4 2024, an increase of $0.3 million, or 5.1% higher than Q3 2024.
    • Operating loss was $2.7 million in Q4 2024, an improvement of $0.4 million, or 12.2% lower than Q3 2024.
    • Net loss was $1.2 million in Q4 2024, an improvement of $2.4 million, or 67.5% lower year over year.
    • Basic and diluted earnings per share in Q4 2024 were ($0.08) an improvement of $0.22 per share compared to Q3 2024.

    Full Year 2024 Highlights:

    • Net revenues for the fiscal year end December 31, 2024 were $28.2 million, down $9.0 million, or 24.2% lower year over year.
    • Operating expenses for the fiscal year end December 31, 2024 were $31.2 million, an improvement of $9.7 million, or 23.7% lower year over year.
    • Operating loss for the fiscal year end December 31, 2024 was $22.1 million, an improvement of $5.9 million, or 21.1% lower from the prior year.
    • Net loss was $22.1 million, an improvement of $6.7 million, or 23.2% lower year over year.
    • Basic and diluted earnings per share were ($1.92) an improvement of $2.22 per share year over year.

    2024 Adjusted EBITDA:

    Our Adjusted EBITDA is a supplemental performance measure of our operations for financial and operational decision-making and is used as a supplemental means of evaluating period-to-period comparisons on a consistent basis. Adjusted EBITDA is calculated as earnings before interest, taxes, depreciation, and amortization, excluding non-recurring transactions, and stock-based compensation.

    Adjusted EBITDA for the year ended December 31, 2024 amounted to a loss of $9.1 million as compared to a loss of $20.2 million for the year ended December 31, 2023. The improved adjusted EBITDA loss was due to the actions taken throughout 2023 and 2024 to better utilize our resources and reduce our expenses.

    A reconciliation of GAAP to non-GAAP measures has been provided in the financial statement tables included in this press release. An explanation of these measures is also included below under the heading "Non-GAAP" Financial Measures.

    "In a short span, Marpai's team engineered an exceptional turnaround, dramatically reducing losses," stated Damien Lamendola, CEO. "Now, we're propelling the Company towards growth and profitability. We are continuing to streamline costs while deploying innovative services, including our recently announced Empara Member Engagement Portal. Looking ahead, we plan to introduce high-impact PBM-based products in the second half of 2025. We believe these actions will fuel revenue growth and position Marpai for profitability in 2025."

    Webcast and Conference Call Information

    Marpai expects to host a conference call and webcast on Thursday, March 27, 2025, at 8:30 a.m. ET to present the Company's operational and financial highlights for its fourth quarter and year ended December 31, 2024.

    You may stream the call via the internet by following this link: https://app.webinar.net/p67nEeDyXjK The webcast replay will be available at the same URL within 2 hours of the end of the call. The replay of the call will be available within 2 hours of the end of the call until April 3, 2025 by calling 1-646-517-4150 or 1-888-660-6345 and entering the replay code, 17670 #.

    About Marpai, Inc.

    Marpai, Inc. (OTCQX:MRAI) is a technology platform company which operates subsidiaries that provide TPA and value-oriented health plan services to employers that directly pay for employee health benefits. Primarily competing in the $22 billion TPA sector serving self-funded employer health plans representing over $1 trillion in annual claims. Through its Marpai Saves initiative, the Company works to deliver the healthiest member population for the health plan budget. Operating nationwide, Marpai offers access to leading provider networks including Aetna and Cigna and all TPA services. For more information, visit www.marpaihealth.com , the content of which is not incorporated by reference into this press release. Investors are invited to visit https://ir.marpaihealth.com.

    Forward-Looking Statement Disclaimer

    This press release contains forward-looking statements, as that term is defined in the Private Litigation Reform Act of 1995, that involve significant risks and uncertainties. Forward-looking statements can be identified through the use of words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance," "may," "can," "could", "will", "potential", "should," "goal" and variations of these words or similar expressions. For example, the Company is using forward-looking statements when it discusses current efforts to propel the Company towards growth and profitability, its plan to introduce high-impact PBM-based products in the second half of 2025, its belief that these actions will fuel revenue growth and position the Company for profitability by the close of 2025, its financial results and its commitment to operational and financial improvements. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect Marpai's current expectations and speak only as of the date of this release. Actual results may differ materially from Marpai's current expectations depending upon a number of factors. These factors include, among others, adverse changes in general economic and market conditions, competitive factors including but not limited to pricing pressures and new product introductions, uncertainty of customer acceptance of new product offerings and market changes, risks associated with managing the growth of the business. Except as required by law, Marpai does not undertake any responsibility to revise or update any forward-looking statements whether as a result of new information, future events or otherwise.

    More detailed information about Marpai and the risk factors that may affect the realization of forward-looking statements is set forth in Marpai's filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov.

    Non-GAAP Financial Measures

    We have provided in this release financial information that has not been prepared in accordance with Generally Accepted Accounting Principles (GAAP). These non-GAAP financial measures are not based on any standardized methodology prescribed by GAAP and are not necessarily comparable to similar measures presented by other companies. We use these non-GAAP financial measures internally in analyzing our financial results and believe they are useful to investors, as a supplement to GAAP measures, in evaluating our ongoing operational performance. We believe that the use of these non-GAAP financial measures provides an additional tool for investors to use in evaluating ongoing operating results and trends and in comparing our financial results with peer companies, many of which present similar non-GAAP financial measures to investors.

    Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with GAAP. Investors are encouraged to review the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures provided in the financial statement tables below.

    Adjusted EBITDA is a supplemental performance measure of our operations for financial and operational decision-making and is used as a supplemental means of evaluating period-to-period comparisons on a consistent basis. Adjusted EBITDA is calculated as earnings before interest, taxes, depreciation, and amortization, excluding non-recurring transactions, and stock-based compensation. We believe these measures provide useful information to management and investors for analysis of our operating results.

    MARPAI, INC. AND SUBSIDIARIES

    CONDENSED CONSOLIDATED BALANCE SHEET

    (in thousands, except share and per share data)







    December 31, 2024



    December 31, 2023











    ASSETS:









    Current assets:









    Cash and cash equivalents



    $                       764



    $                          1,147

    Restricted cash



    8,468



    12,345

    Accounts receivable, net of allowance for credit losses of $1 and $25



    837



    1,124

    Unbilled receivable



    569



    768

    Due from buyer for sale of business unit



    500



    800

    Prepaid expenses and other current assets



    759



    901

    Total current assets



    11,897



    17,085











    Property and equipment, net



    —



    611

    Capitalized software, net



    441



    2,127

    Operating lease right-of-use assets



    296



    2,373

    Goodwill



    —



    3,018

    Intangible assets, net



    —



    5,177

    Security deposits 



    229



    1,267

    Other long-term asset



    15



    22

    Total assets



    $                  12,878



    $                        31,680

    LIABILITIES AND STOCKHOLDERS'  DEFICIT









    Current liabilities:









    Accounts payable



    $                    3,109



    $                          4,649

    Accrued expenses



    2,585



    2,816

    Accrued fiduciary obligations



    6,308



    11,573

    Deferred revenue



    625



    661

    Current portion of operating lease liabilities



    244



    512

    Current portion of convertible debentures, net



    3,106



    —

    Other short-term liabilities



    3,005



    632

    Total current liabilities



    18,982



    20,843











    Other long-term liabilities



    14,891



    19,401

    Convertible debentures, net of current portion



    5,921



    —

    Operating lease liabilities, net of current portion



    793



    3,684

    Deferred tax liabilities



    —



    1,190

    Total liabilities



    40,587



    45,118

    COMMITMENTS AND CONTINGENCIES









    STOCKHOLDERS' DEFICIT









    Common stock, $0.0001 par value, 227,791,050 shares authorized; 14,237,176 issued

    and outstanding at December 31, 2024 and 7,960,938 issued and outstanding at

    December 31, 2023



    1



    1

    Additional paid-in capital



    71,124



    63,307

    Accumulated deficit



    (98,834)



    (76,746)

    Total stockholders' deficit



    (27,709)



    (13,438)

    Total liabilities and stockholders' deficit



    $                  12,878



    $                        31,680











     

    MARPAI, INC. AND SUBSIDIARIES

    CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

    (in thousands, except share and per share data)







    Year ended 



    Three Months Ended 





    December 31, 2024



    December 31,

    2023



    December 31,

    2024



    December 31, 2023

    Revenue



    $                  28,173



    $                        37,155



    $        6,591



    $     8,707

    Costs and expenses

















    Cost of revenue (exclusive of depreciation and amortization

       shown separately below)



    19,066



    24,239



    3,988



    5,709

    General and administrative



    12,832



    19,177



    2,878



    3,239

    Sales and marketing



    1,766



    6,597



    383



    1,103

    Information technology



    4,697



    5,834



    1,089



    1,059

    Research and development



    29



    1,311



    7



    21

    Depreciation and amortization



    2,256



    3,897



    178



    923

    Impairment of goodwill and intangible assets



    7,588



    3,018



    —



    3,018

    Facilities



    1,305



    2,472



    108



    554

    Loss on disposal of assets



    648



    335



    648



    (15)

    Loss (gain) on sale of business unit



    73



    (1,748)



    —



    (1,749)

    Total costs and expenses



    50,260



    65,132



    9,279



    13,862

    Operating loss



    (22,087)



    (27,977)



    (2,688)



    (5,155)

    Other income (expenses)

















    Other income



    396



    488



    36



    258

    Interest expense, net



    (2,709)



    (1,527)



    (819)



    (425)

    Loss on debt extinguishment



    (1,877)



    —



    (1,877)



    —

    Gain on forgiveness of other liability



    3,000



    —



    3,000



    —

    Foreign exchange loss



    (1)



    (26)



    2



    6

    Loss before provision for income taxes



    (23,278)



    (29,042)



    (2,346)



    (5,316)

    Income tax expense



    (1,190)



    (290)



    (1,190)



    (290)

    Net loss



    $                (22,088)



    $                      (28,752)



    $      (1,156)



    $    (5,026)

    Net loss per share, basic & fully diluted



    $                    (1.92)



    $                          (4.14)



    $        (0.08)



    $      (0.65)

    Weighted average common shares outstanding, basic and

       diluted



    11,511,203



    6,951,669



    13,934,066



    7,738,879



















     

    MARPAI, INC. AND SUBSIDIARIES

    CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

    (in thousands, except share and per share data)







    Year ended





    December 31, 2024



    December 31, 2023

    Cash flows from operating activities:









    Net loss



    $                (22,088)



    $                      (28,752)

    Adjustments to reconcile net loss to net cash used in operating activities:









    Depreciation and amortization



    2,256



    3,897

    Loss on disposal of assets



    648



    335

    Loss on sale of receivables



    306



    —

    Share-based compensation



    3,157



    2,099

    Warrant expense



    —



    242

    Shares issued to vendors in exchange for services



    —



    79

    Amortization of right-of-use asset



    211



    1,502

    Impairment of goodwill and intangible assets



    7,588



    3,018

    Loss/(gain) on sale of business unit



    73



    (1,749)

    Gain on forgiveness of other liability



    (3,000)



    —

    Loss on termination of lease



    71



    —

    Non-cash interest expense



    1,395



    1,527

    Amortization of debt discount and debt issuance costs



    201



    —

    Loss on debt extinguishment



    1,877



    —

    Deferred taxes



    (1,190)



    (290)

    Changes in operating assets and liabilities:









    Accounts receivable and unbilled receivable



    486



    (105)

    Prepaid expense and other assets



    142



    732

    Security deposit



    138



    27

    Accounts payable



    (1,540)



    3,191

    Accrued expenses



    (231)



    (2,497)

    Accrued fiduciary obligations



    (5,265)



    2,548

    Operating lease liabilities



    (464)



    (1,887)

    Due To related party



    —



    (3)

    Other liabilities



    64



    337

    Other asset



    7



    —

    Net cash used in operating activities



    (15,158)



    (15,749)

    Cash flows from investing activities:









    Proceeds from sale of business unit



    227



    1,000

    Proceeds from disposal of property and equipment



    —



    27

    Net cash provided by investing activities



    227



    1,027

    Cash flows from financing activities:









    Proceeds from issuance of common stock in a public offering, net



    —



    6,432

    Payments to seller for acquisition



    (631)



    (1,663)

    Proceeds from issuance of warrants



    —



    32

    Proceeds from issuance of common stock in a private offering, net



    4,660



    295

    Proceeds from issuance of convertible debentures



    8,000



    —

    Proceeds from sale of future cash receipts on accounts receivable



    1,509



    —

    Payments to buyer of receivables



    (1,816)



    —

    Payments on convertible debentures



    (420)



    —

    Payments of convertible debenture issuance costs



    (631)



    —

    Net cash provided by financing activities



    10,671



    5,096











    Net decrease in cash, cash equivalents and restricted cash



    (4,260)



    (9,626)











    Cash, cash equivalents and restricted cash at beginning of period



    13,492



    23,118

    Cash, cash equivalents and restricted cash at end of period



    $                    9,232



    $                        13,492











    Reconciliation of cash, cash equivalents, and restricted cash reported in

       the condensed consolidated balance sheet









    Cash and cash equivalents



    $                       764



    $                          1,147

    Restricted cash



    8,468



    12,345

    Total cash, cash equivalents and restricted cash shown in the condensed

       consolidated statement of cash flows



    $                    9,232



    $                        13,492

    Supplemental disclosure of cash flow information









    Cash paid for interest



    $                    1,742



    $                               —

    Supplemental disclosure of non-cash activity investing and financing activities









    Measurement period adjustment to Goodwill



    $                         —



    $                              198











     

    MARPAI, INC. AND SUBSIDIARIES

    Reconciliation of Net Loss to EBITDA, and Adjusted EBITDA 

    (in thousands, except share and per share data)







    Year ended





    December 31, 2024



    December 31, 2023

    Net Loss



    $                (22,088)



    $                      (28,752)

    Other income, net



    (396)



    (488)

    Interest expense



    2,709



    1,527

    Loss on debt extinguishment



    1,877



    —

    Gain on forgiveness of other liability



    (3,000)



    —

    Foreign exchange loss



    1



    26

    Provision for taxes



    (1,190)



    (290)

    Depreciation and amortization



    2,256



    3,897

    EBITDA



    $                (19,831)



    $                      (24,080)

    Impairment of goodwill and intangible assets



    7,588



    3,018

    Loss on disposal of asset



    648



    335

    Loss (gain) on sale of business unit



    73



    (1,748)

    Stock-based compensation



    2,465



    2,294

    Adjusted EBITDA



    $                  (9,057)



    $                      (20,181)











     

    (PRNewsfoto/Marpai)

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/marpai-reports-fourth-quarter-and-full-year-2024-financial-results-302412484.html

    SOURCE Marpai

    Get the next $MRAI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MRAI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MRAI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • MARPAI REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS

      Marpai's turnaround momentum is building TAMPA, Fla., May 14, 2025 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (OTCQX:MRAI), a leader in innovative healthcare technology and Third-Party Administration (TPA) services, announced financial results for the first quarter of 2025. The Company expects to hold a webcast to discuss the results on May 15, 2025. Marpai CEO Damien Lamendola commented, "Our consistent double-digit success in cutting operating expenses and improving our bottom line signals what we believe is a critical inflection point for the Company. Looking ahead to the second quarter, we are focused on completing several key initiatives, including the launch of our Health

      5/14/25 4:07:00 PM ET
      $MRAI
      Misc Health and Biotechnology Services
      Health Care
    • MARPAI HIRES DALLAS SCRIP AS CHIEF OPERATING OFFICER

      Marpai Bolsters Leadership Team to Drive Profitable High-Growth Strategy with Key Executive Appointment  TAMPA, Fla., May 13, 2025 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (OTCQX:MRAI), a leader in innovative healthcare technology and Third-Party Administration (TPA) services, today announced a significant addition to its leadership team with the appointment of Dallas Scrip as Chief Operating Officer (COO) and President of MarpaiRx. This strategic hire underscores Marpai's commitment to accelerating profitable growth and enhancing operational excellence within the dynamic healthcare landscape. Prior to joining Marpai, Mr. Scrip demonstrated significant success in startup, ear

      5/13/25 9:01:00 AM ET
      $MRAI
      Misc Health and Biotechnology Services
      Health Care
    • MARPAI TO HOST WEBCAST ON MAY 15, 2025 TO DISCUSS FIRST QUARTER 2025 FINANCIAL RESULTS

      TAMPA, Fla., May 7, 2025 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (OTCQX:MRAI), a leader in innovative healthcare technology and Third-Party Administration (TPA) services. The Company will host a conference call and webcast on Thursday, May 15 at 8:30 a.m. ET to present the Company's operational and financial highlights for Q1 2025. The Company will report its first quarter 2025 results on Wednesday after the market close. Event: Marpai 2025 Q1 Financial Results Conference Call Date: May 15, 2025 Time: 8:30 a.m. Eastern Time Call:    US: 1-646-357-8785 / Toll Free: 1-800-836-8184 Webcast:    https://app.webinar.net/e6RGaxOgz3n Follow us on X.com and LinkedIn You may stream th

      5/7/25 4:03:00 PM ET
      $MRAI
      Misc Health and Biotechnology Services
      Health Care

    $MRAI
    SEC Filings

    See more
    • SEC Form 10-Q filed by Marpai Inc.

      10-Q - Marpai, Inc. (0001844392) (Filer)

      5/14/25 4:20:40 PM ET
      $MRAI
      Misc Health and Biotechnology Services
      Health Care
    • Marpai Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Marpai, Inc. (0001844392) (Filer)

      5/14/25 4:15:36 PM ET
      $MRAI
      Misc Health and Biotechnology Services
      Health Care
    • Marpai Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits

      8-K - Marpai, Inc. (0001844392) (Filer)

      5/13/25 9:23:22 AM ET
      $MRAI
      Misc Health and Biotechnology Services
      Health Care

    $MRAI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Lamendola Damien was granted 600,000 shares (SEC Form 4)

      4 - Marpai, Inc. (0001844392) (Issuer)

      1/29/25 4:01:10 PM ET
      $MRAI
      Misc Health and Biotechnology Services
      Health Care
    • New insider Intelligent Fanatics Capital Management Llc claimed ownership of 3,729,414 shares (SEC Form 3)

      3 - Marpai, Inc. (0001844392) (Issuer)

      1/2/25 9:41:02 AM ET
      $MRAI
      Misc Health and Biotechnology Services
      Health Care
    • President and COO Powers John Paul was granted 100,000 shares and bought $11,300 worth of shares (10,000 units at $1.13), increasing direct ownership by 73% to 260,000 units (SEC Form 4)

      4 - Marpai, Inc. (0001844392) (Issuer)

      12/9/24 5:15:20 PM ET
      $MRAI
      Misc Health and Biotechnology Services
      Health Care

    $MRAI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President and COO Powers John Paul was granted 100,000 shares and bought $11,300 worth of shares (10,000 units at $1.13), increasing direct ownership by 73% to 260,000 units (SEC Form 4)

      4 - Marpai, Inc. (0001844392) (Issuer)

      12/9/24 5:15:20 PM ET
      $MRAI
      Misc Health and Biotechnology Services
      Health Care
    • Chief Financial Officer Johnson Steve Andrew was granted 100,000 shares and bought $5,650 worth of shares (5,000 units at $1.13), increasing direct ownership by 29% to 473,061 units (SEC Form 4)

      4 - Marpai, Inc. (0001844392) (Issuer)

      12/9/24 5:14:54 PM ET
      $MRAI
      Misc Health and Biotechnology Services
      Health Care
    • Director Eitan Yaron was granted 5,000 shares and bought $124,999 worth of shares (110,619 units at $1.13), increasing direct ownership by 17% to 789,073 units (SEC Form 4)

      4 - Marpai, Inc. (0001844392) (Issuer)

      12/9/24 5:14:32 PM ET
      $MRAI
      Misc Health and Biotechnology Services
      Health Care

    $MRAI
    Financials

    Live finance-specific insights

    See more
    • MARPAI REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS

      Marpai's turnaround momentum is building TAMPA, Fla., May 14, 2025 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (OTCQX:MRAI), a leader in innovative healthcare technology and Third-Party Administration (TPA) services, announced financial results for the first quarter of 2025. The Company expects to hold a webcast to discuss the results on May 15, 2025. Marpai CEO Damien Lamendola commented, "Our consistent double-digit success in cutting operating expenses and improving our bottom line signals what we believe is a critical inflection point for the Company. Looking ahead to the second quarter, we are focused on completing several key initiatives, including the launch of our Health

      5/14/25 4:07:00 PM ET
      $MRAI
      Misc Health and Biotechnology Services
      Health Care
    • MARPAI TO HOST WEBCAST ON MAY 15, 2025 TO DISCUSS FIRST QUARTER 2025 FINANCIAL RESULTS

      TAMPA, Fla., May 7, 2025 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (OTCQX:MRAI), a leader in innovative healthcare technology and Third-Party Administration (TPA) services. The Company will host a conference call and webcast on Thursday, May 15 at 8:30 a.m. ET to present the Company's operational and financial highlights for Q1 2025. The Company will report its first quarter 2025 results on Wednesday after the market close. Event: Marpai 2025 Q1 Financial Results Conference Call Date: May 15, 2025 Time: 8:30 a.m. Eastern Time Call:    US: 1-646-357-8785 / Toll Free: 1-800-836-8184 Webcast:    https://app.webinar.net/e6RGaxOgz3n Follow us on X.com and LinkedIn You may stream th

      5/7/25 4:03:00 PM ET
      $MRAI
      Misc Health and Biotechnology Services
      Health Care
    • MARPAI TO HOST WEBCAST ON MARCH 27, 2025 TO DISCUSS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS

      TAMPA, Fla., March 20, 2025 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (OTCQX:MRAI), a technology platform company, operates as a national Third-Party Administrator (TPA) through its subsidiaries. We're transforming the $22 billion TPA market by offering affordable, intelligent, healthcare solutions to self-funded employer health plans. The Company will host a conference call and webcast on Thursday, March 27 at 8:30 a.m. ET to present the Company's operational and financial highlights for 2024. The Company will report its fourth quarter and full year 2024 results on Wednesday after the market close. Event: Marpai 2024 Financial Results Conference Call Date: March 27, 2025 Time

      3/20/25 8:32:00 AM ET
      $MRAI
      Misc Health and Biotechnology Services
      Health Care

    $MRAI
    Leadership Updates

    Live Leadership Updates

    See more
    • MARPAI HIRES DALLAS SCRIP AS CHIEF OPERATING OFFICER

      Marpai Bolsters Leadership Team to Drive Profitable High-Growth Strategy with Key Executive Appointment  TAMPA, Fla., May 13, 2025 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (OTCQX:MRAI), a leader in innovative healthcare technology and Third-Party Administration (TPA) services, today announced a significant addition to its leadership team with the appointment of Dallas Scrip as Chief Operating Officer (COO) and President of MarpaiRx. This strategic hire underscores Marpai's commitment to accelerating profitable growth and enhancing operational excellence within the dynamic healthcare landscape. Prior to joining Marpai, Mr. Scrip demonstrated significant success in startup, ear

      5/13/25 9:01:00 AM ET
      $MRAI
      Misc Health and Biotechnology Services
      Health Care
    • Health In Tech Announces Innovative Collaboration with MARPAI and Vitable DPC to Offer Competitive Quotes in Enhanced Self-Funded Solutions

      STUART, Fla., Jan. 22, 2025 /PRNewswire/ -- Health In Tech, an Insurtech platform company backed by third-party AI technology, is thrilled to announce a new strategic collaboration with Vitable and MARPAI. This collaboration aims to introduce a  competitively priced self-funded health plan to the market. By utilizing the strength of Vitable's Direct Primary Care (DPC), a health plan, and stop-loss coverage, Health In Tech seeks to offer low quotes on their eDIYBS platform, and to set an ambitious standard in affordability and efficiency. Vitable's enhanced primary care plan co

      1/22/25 5:00:00 PM ET
      $HIT
      $MRAI
      Specialty Insurers
      Finance
      Misc Health and Biotechnology Services
      Health Care
    • George Economou Files Definitive Proxy Statement and Sends Letter to Genco Shareholders

      Highlights Urgent Need for An Independent Director Perspective to Address Genco's Persistent Underperformance and Unlock Value for Shareholders Outlines Concerns with Chairman James Dolphin's Outsized Influence in the Genco Boardroom Urges Shareholders to Vote FOR the Election of GK Investor Nominee Robert Pons on the BLUE Universal Proxy Card and WITHHOLD on Genco Board Chairman James Dolphin GK Investor LLC ("GK"), an affiliate of George Economou that is an approximately 5.3% shareholder of Genco Shipping & Trading Limited ("Genco" or the "Company") (NYSE:GNK), today announced that it has filed its definitive proxy statement with the U.S. Securities and Exchange Commission in connec

      4/18/24 1:07:00 PM ET
      $GNK
      $INSG
      $MRAI
      $SEAC
      Marine Transportation
      Consumer Discretionary
      Telecommunications Equipment
      Telecommunications

    $MRAI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Marpai Inc.

      SC 13D/A - Marpai, Inc. (0001844392) (Subject)

      12/9/24 5:14:07 PM ET
      $MRAI
      Misc Health and Biotechnology Services
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Marpai Inc.

      SC 13D/A - Marpai, Inc. (0001844392) (Subject)

      9/4/24 7:55:41 PM ET
      $MRAI
      Misc Health and Biotechnology Services
      Health Care
    • SEC Form SC 13D/A filed by Marpai Inc. (Amendment)

      SC 13D/A - Marpai, Inc. (0001844392) (Subject)

      5/29/24 4:01:02 PM ET
      $MRAI
      Misc Health and Biotechnology Services
      Health Care